반응 #1135406

ord-d40b12050db74ef5ae09c5f389656cb9

용매

반응 조건

상세 조건
See reaction.notes.procedure_details.

후처리

  1. 1
    기타solvents were removed under reduced pressure
  2. 2
    기타the residual TFA was removed
  3. 3
    기타by azeotroping with toluene under reduced pressure three times
  4. 4
    기타Separation of the crude product by reversed phase HPLC (45 to 70% AcCN/H2O in 30 min, 3 time runs, tR=18.52 min)

실험 절차

To a solution of 57 mg (0.11 mmol) of tert-butyl 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-cyanopentan-3-yl)-2-oxopiperidin-3-yl)acetate (Example 30, Step B) in DCM (359 μL) was added trifluoroacetic acid (415 μL, 5.38 mmol) at 0° C. After being stirred at 25 C for 2 h, solvents were removed under reduced pressure and the residual TFA was removed by azeotroping with toluene under reduced pressure three times. Separation of the crude product by reversed phase HPLC (45 to 70% AcCN/H2O in 30 min, 3 time runs, tR=18.52 min) provided the title compound as a white solid.

출처

DOI: 10.6084/m9.figshare.5104873.v1특허: US08569341B2uspto-grants-2013_10